Howard S Hochster

23PUBLICATIONS
125CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Development cooperationPrivate law and civil obligations not elsewhere classifiedMolecular targetsEcohydrology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Jul 29, 2026
COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

|Jun 08, 2026
Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

|Jun 08, 2026
Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

|Jan 07, 2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Van K Morris, Kristen K Ciombor, Lianchun Xiao

|Dec 06, 2025
Real-world vs unreal eligibility.

Howard S Hochster

|Oct 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.

Robert W Lentz, Julie Lang, Todd M Pitts

Pageof 4

Frequent Collaborators

4 joint publications

Aaron J Scott

3 joint publications

Scott Kopetz

3 joint publications

E Gabriela Chiorean

3 joint publications

Heinz-Josef Lenz